Clear All
757 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9040 Bleomycin Bleomycin 15 units Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1973 Jan 1, 1984 In Use
J2469 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan 1, 2005 In Use
NA Pazopanib Votrient 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT, Lck, FMS Yes 2009 In Use
J9296 Pemetrexed (Accord) Pemetrexed (Accord) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9044 Bortezomib Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2019 Nov 3, 2019 Dec 21, 2022 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Trifluridine and Tipiracil Lonsurf 20/ 8.19 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
J9027 Clofarabine Clolar 1 mg Chemotherapy Antimetabolite Purine Analog No 2004 Jan 1, 2006 In Use
J9075 Cyclophosphamide (nos) Cyclophosphamide (nos) 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Apr 17, 2024 In Use
J9178 Epirubicin Epirubicin 2 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1999 Jan 1, 2004 In Use
J2919 Methylprednisolone sodium succinate Methylprednisolone sodium succinate 5mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1959 Apr 17, 2024 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.625 mg Hormonal Therapy Estrogen Yes 1977 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 Jul 1, 2020 In Use
Q5127 Pegflilgrastim-fpgk Stimufend 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan 1, 2010 In Use
NA Finasteride Proscar 5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 1992 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Selumetinib Koselugo 10mg, 25mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2020 In Use
J9098 Cytarabine Cytarabine Liposome 10 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1999 Jan 1, 2004 In Use
J9322 Pemetrexed (Bluepoint) Pemetrexed (Bluepoint) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
NA Cyclosporine Gengraf 25mg, 50mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 2010 In Use
NA Glasdegib Daurismo 25mg, 100mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2018 In Use
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.